Simeprevir + Daclatasvir in HCV GT1b With Advanced Disease Simeprevir + Daclatasvir in HCV GT1b With Advanced Disease

This study investigated the efficacy and safety of simeprevir plus daclatasvirin in a population of treatment-naive patients with chronic GT1b HCV infection with advanced fibrosis or cirrhosis.Liver International

Source: Medscape Today Headlines - December 15, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news